This study provides important clinical evidence for advanced thyroid cancer, particularly for ATC patients with unmet treatment needs, suggesting that combined PD-L1 and CTLA-4 blockade may be a rational direction for future exploration of immunotherapy strategies.
Literature Overview
The article titled 'Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial,' published in Nature Communications, systematically investigates the efficacy and safety of combining the anti-PD-L1 antibody durvalumab with the anti-CTLA-4 antibody tremelimumab in patients with refractory advanced thyroid cancer. The study employs a single-arm, multi-cohort design, enrolling patients with differentiated (DTC), medullary (MTC), and anaplastic (ATC) subtypes, aiming to evaluate the clinical benefit of dual immune checkpoint inhibition. Results show that the combination met the primary endpoint in the ATC cohort, demonstrating promising survival benefits, while showing limited efficacy in DTC and MTC. The study also highlights current challenges in immunotherapy for thyroid cancer and potential directions for biomarker exploration.Background Knowledge
Thyroid cancer is the most common endocrine malignancy, with significant pathological heterogeneity—ranging from DTC, which has a favorable prognosis, to ATC, which is highly aggressive and has a median overall survival of less than one year—leading to vastly different treatment needs. Although multi-kinase inhibitors (MKIs) have become standard treatments for DTC and MTC, effective options remain limited for patients progressing after these therapies. While RET inhibitors and NTRK inhibitors have improved outcomes in specific molecular subgroups, treatment options after resistance development are extremely limited. Immune checkpoint inhibitors (ICIs) have shown limited monotherapy efficacy in tumors with moderate immunogenicity; thus, dual blockade targeting PD-1/PD-L1 and CTLA-4 has emerged as a strategy to enhance antitumor immunity. Preliminary studies in neuroendocrine tumors suggest that the combination of durvalumab and tremelimumab has manageable safety and some activity, providing a theoretical basis for exploring its use in thyroid cancer. However, it remains unclear which subtypes or biomarkers can predict ICI efficacy, and prospective data guiding treatment selection are lacking. This study addresses this unmet clinical need by focusing on ATC—a highly aggressive subtype with no effective treatments—while also evaluating the potential of this regimen in later-line therapy for DTC and MTC.
Research Methods and Experiments
The study adopted a phase II, single-arm, multi-cohort design, enrolling 79 patients with advanced thyroid cancer, divided into three cohorts: DTC (n=37), MTC (n=30), and ATC (n=12). The treatment regimen consisted of durvalumab (1500 mg IV q4w) combined with tremelimumab (75 mg IV q4w) for the first four cycles, followed by durvalumab monotherapy maintenance. The primary endpoints were the 6-month PFS rate for the DTC and MTC cohorts and the 6-month OS rate for the ATC cohort. Tumor responses were assessed every 12 weeks using RECIST v1.1, and efficacy analyses—including PFS, OS, and ORR—were performed on the full analysis set (FAS). Safety was evaluated using NCI-CTCAE v5.0. Additionally, exploratory biomarker analyses were conducted, including PD-L1 expression (CPS ≥1 defined as positive), MSI status, and BRAF and RET mutation testing, to identify potential predictive factors. This design effectively evaluated clinical activity in a real-world refractory population while accounting for the heterogeneity across subtypes.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides new clinical evidence for the treatment of ATC, suggesting that dual immune checkpoint inhibition could become one of the therapeutic options for this aggressive subtype, especially in the absence of effective targeted therapies. Future studies may explore combination strategies of PD-1 inhibitors with targeted therapies (e.g., BRAF/MEK inhibitors) to enhance antigen presentation and T-cell infiltration, thereby improving efficacy. Moreover, the study suggests that PD-L1 and MSI may serve as predictive biomarkers, recommending inclusion of more comprehensive immune profiling in future research—such as TMB and TIL infiltration—to establish more precise patient selection models.
Conclusion
The GETNE-DUTHY phase II trial confirms that durvalumab combined with tremelimumab delivers clinically meaningful survival benefits in patients with advanced ATC, achieving a 6-month OS rate of 65.6% and a median OS of 13.8 months, offering new hope for this group with extremely poor prognosis. Although efficacy is limited in DTC and MTC, the study still provides key prospective data on immunotherapy in thyroid cancer. It underscores the importance of tumor subtype-specific treatment strategies and suggests that PD-L1 and MSI may serve as potential biomarkers to guide the development of precision immunotherapies. From bench to bedside, this study lays the foundation for building more effective immunotherapy models for ATC, recommending integration of tumor microenvironment analysis and exploration of novel combination regimens to further enhance therapeutic outcomes. Meanwhile, for DTC and MTC, other immune-modulating strategies or combination targeted therapies should be explored to overcome resistance mechanisms. Overall, this study advances personalized therapy in thyroid cancer, particularly by offering a new cornerstone option for the management of ATC patients.
